BIO.News Newsletter

It's been a busy week at BIO's IP Conference – here's what we've learned so far. (735 words, 3 minutes, 40 seconds)

We’re heading to Southern California to cover the BIO IP Conference—and why biotech needs strong patents. Here’s what we’re watching, plus a recap of BIO on the American Road in Indiana. (853 words, 4 minutes, 15 seconds)

Patient advocates say transparency will help the 340B program realign with its original intent of helping patients. Also, thoughts on supporting small molecules achieving big results. (735 words, 3 minutes, 40 seconds)

How can smart policy secure America’s leadership in biotechnology? BIO President & CEO John F. Crowley outlined the path forward in Senate testimony and a joint op-ed with Sen. Todd Young (R-IN). (703 words, 3 minutes, 30 seconds)

We look back on the BIO Patient Advocacy Changemaker Event (PACE) in Washington, D.C.—here’s what we learned. (700 words, 3 minutes, 30 seconds)

BIO’s Patient Advocacy Changemakers Event (PACE) begins today in Washington, D.C.—here’s what we’re watching. Plus, new studies highlight the extra benefits of COVID mRNA and shingles vaccines. (683 words, 3 minutes, 24 seconds)

Lack of vaccination is allowing a measles comeback. Also, a sickle cell advocate explains why speaking out matters. (637 words, 3 minutes, 11 seconds)

A Senate hearing promotes legislation that would provide clarity on patents. Also: heroism and advocacy around arthritis. (670 words, 3 minutes, 21 seconds)

A Most Favored Nation (MFN) pricing agreement was announced—here’s what BIO’s saying about it. Plus, we recap BIO on the American Road in Illinois. (615 words, 3 minutes, 4 seconds)

President Trump announced pharmaceutical tariffs. Also, we continue our series on drug pricing in the U.S. (730 words, 3 minutes, 39 seconds)